Resveratrol analogue HS-1793 induces the modulation of tumor-derived T cells

Experimental and Therapeutic Medicine

Volumn 3, Issue 4, 2012, Pages 592-598

  Choi, Yoo Jin ^a   Yang, Kwang Mo ^a   Kim, Sung Dae ^a   Yoo, Young Hyun ^b   Lee, Sang Wha ^b   Seo, Su Yeong ^b   Suh, Hongsuk ^c   Yee, Sung Tae ^d   Jeong, Min Ho ^b   Jo, Wol Soon ^a  

^a Dongnam Institute of Radiological and Medical Science   (South Korea)

^b Dong A University College of Medicine   (South Korea)

^c Pusan National University   (South Korea)

^d Sunchon National University   (South Korea)

Author keywords

FoxP3; Hs 1793; Interferon ; Regulatory T cell; Resveratrol analogue

Indexed keywords

CONCANAVALIN A; GAMMA INTERFERON; HS 1793; INTERLEUKIN 2; INTERLEUKIN 4; RESVERATROL; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFECT; FEMALE; IMMUNE RESPONSE; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PHENOTYPE; REGULATORY T LYMPHOCYTE; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84863045339     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.472     Document Type: Article

References (34)

1. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
2. Raza SA, Clifford GM and Franceschi S: Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. Br J Cancer 96: 1127-1134, 2007.
3. Odunsi K and Old LJ: Tumor infiltrating lymphocytes: indicators of tumor-related immune responses. Cancer Immun 7: 3, 2007.
4. Zou W: Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5: 263-274, 2005.
5. Yu P and Fu YX: Tumor-infiltrating T lymphocytes: friends or foes? Lab Invest 86: 231-245, 2006.
6. Zou W: Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6: 295-307, 2006.
7. Beyer M and Schultze JL: Regulatory T cells in cancer. Blood 108: 804-811, 2006.
8. + regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 8: 1002-1008, 2007.
9. + T cells impinge on tumor immunobiology: the differential response of tumors to therapies. J Immunol 179: 5659-5668, 2007.
10. Curiel TJ: Regulatory T cells and treatment of cancer. Curr Opin Immunol 20: 241-246, 2008.
11. Liu Z, Kim JH, Falo LD Jr and You Z: Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol 182: 6160-6167, 2009.
12. Malmberg KJ: Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53: 879-892, 2004.
13. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
14. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S and Takada Y: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004.
15. Bove K, Lincoln DW and Tsan MF: Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 291: 1001-1005, 2002.
16. Feng YH, Zhou WL, Wu QL, Li XY, Zhao WM and Zou JP: Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol Sin 23: 893-897, 2002.
17. Song S, Lee H, Jin Y, Ha YM, Bae S, Chung HY and Suh H: Syntheses of hydroxy substituted 2-phenyl-naphthalenes as inhibitors of tyrosinase. Bioorg Med Chem Lett 17: 461-464, 2007.
18. Jeong SH, Jo WS, Song S, Suh H, Seol SY, Leem SH, Kwon TK and Yoo YH: A novel resveratrol analog, HS-1793, overcomes the resistance conferred by Bcl-2 in human leukemic U937 cells. Biochem Pharmacol 7: 1337-1347, 2009.
19. + regulatory T cells. Int Immunopharmacol 8: 542-547, 2008.
20. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 162: 5317-5326, 1999.
21. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 10: 1969-1980, 1998.
22. + regulatory T cell function. Eur J Immunol 34: 2480-2488, 2004.
23. + regulatory T cell function. J Exp Med 196: 851-857, 2002.
24. Yao Z, Kanno Y, Kerenyi M, Stephens G, Durant L, Watford WT, Laurence A, Robinson GW, Shevach EM, Moriggl R, Hennighausen L, Wu C and O'Shea JJ: Nonredundant roles for Stat5a/b in directly regulating Foxp3. Blood 109: 4368-4375, 2007.
25. + Foxp3-effector T cells. Nat Immunol 9: 1347-1355, 2008.
26. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
27. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME and Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782, 2004.
28. Alpan O, Bachelder E, Isil E, Arnheiter H and Matzinger P: 'Educated' dendritic cells act as messengers from memory to naive T helper cells. Nat Immunol 5: 615-622, 2004.
29. + T cell memory. Science 297: 2060-2063, 2002.
30. Xiaoyu H and Lionel BL: Cross-regulation of signaling pathway by interferon-γ: implication for immune response and autoimmune diseases. Immunity 31: 593-550, 2009.
31. Park YS, Bae JH, Son CH, Lee KS, Kim W, Jung MH, Yang K, Kim SH and Kang CD: Cyclophosphamide potentiates the antitumor effect of immunization with injection of immature dendritic cells into irradiated tumor. Immunol Invest 40: 383-399, 2011.
32. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS and Linehan DC: Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002.
33. + regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clin Cancer Res 13: 2714-2721, 2007.
34. Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E and Disis ML: IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 177: 84-91, 2006.